Table 2.
Medication characteristics of flare and control cases being used at time of flare for flare cases and their matched controls.
Flares (n = 74) | Controls (n = 74) | P value | |
---|---|---|---|
Taking ≥ 1 IBD medication | 81.1% | 85.1% | 0.510 |
No. IBD medications mean (SD) | 1.30 (1.17) | 1.18 (0.82) | 0.464 |
Immunosuppressant (Ex: Methotrexate) | 27.0% | 21.6% | 0.443 |
5-ASA | 23.0% | 25.7% | 0.702 |
ustekinumab | 5.4% | 8.1% | 0.512 |
Anti-TNF agent | 27.0% | 33.8% | 0.372 |
vedolizumab | 0.0% | 1.4% | 0.316 |
Other IBD medication | 28.4% | 18.9% | 0.161 |
Changed medication/dosage ± 4 weeks of flare | 39.2% | 9.5% | 0.000 |
Introduced oral corticosteroid ± 4 weeks of flare | 21.6% | 6.8% | 0.010 |